Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.
Watch this video where our CFO, Sibaji Biswas, shares his perspective on a trend-breaking year with revenue growth of 23% year-on-year. Syngene delivered the highest absolute year-on-year increase in revenue and EBITDA compared to the last five years. While the research business and Dedicated Centers delivered a strong performance, Development and Manufacturing services grew by 28% year-on-year. To read the full press release, click here.
Watch this video where our MD and CEO, Jonathan Hunt, shares his perspective on the financial year gone by and the outlook for FY24. Syngene’s sustained positive performance in the fourth quarter delivered strong full-year results. Revenue from operations in Q4 grew by 31%, while full-year revenue from operations in FY 23 grew by 23%. To read the press release, click here.
Syngene reported a 19% growth in revenue from operations for the entire year of FY22. Watch this video as our CEO and MD, Jonathan Hunt, speaks about Syngene’s performance, the outlook for FY 23, Syngene’s contribution in the fight against the pandemic, focus areas for the coming year, and more.
Catch a glimpse of our ~ 2 Mn sq. ft. world-class R&D and manufacturing facility to understand how we put Science to Work at Syngene. We are an innovation-led, contract research, development & manufacturing organization offering integrated scientific services from early discovery to commercial supply.
Watch this video on our Early-stage Chemistry Process Research Lab for drug discovery that supports pre-clinical studies, medicinal chemistry, and integrated project requirements (from mg to kg scale).
Syngene reported a 19% growth in revenue from operations for the full year (FY22). Watch this video to learn more about our performance, business highlights, awards & recognitions, and more.
In this video, Syngene scientist Saurabh Sahu takes you through the capabilities and features of our integrated Sterile Fill-Finish facility for clinical supplies of Biologics and Small Molecules, as well as, products that are sensitive to light, heat and oxygen.
Syngene reported 12% growth in revenue from operations for the full year of FY21. Watch this video, to know more about our company performance, business highlights, COVID-19 updates and more.
Want to know, how Syngene conducts RT-PCR testing at its COVID-19 Testing laboratory? Approved by Indian Council of Medical Research (ICMR), this lab has tested more than 100000+ samples so far.
Explore Syngene’s Large Molecule Bioanalytical Laboratory, which is India’s premier GLP- certified and GCLP-compliant lab. It specializes in immunogenicity and pharmacokinetic (PK) analysis of biologics and biosimilars.
Explore our new 52,000 sq.ft., state-of-the-art R&D center in Genome valley, Hyderabad. Focused on Discovery Chemistry services, we are excited to be expanding our facilities to assist more clients accelerate their research programs.
Our GMP-certified, API manufacturing facility in Mangaluru is a state-of-the-art, multi-product, multi-client, contract facility. Spread across 46 acres, it is designed to support all large-scale API and advanced intermediate manufacturing requirements of our clients.